Samuel Agresta, M.D., MPH serves as Infinity’s chief medical officer. Dr. Agresta joined Infinity as chief medical officer in August 2018. He has more than 10 years of experience in global clinical drug development in solid tumors and hematologic malignancies, including the recent approval of several cancer medicines. Prior to joining Infinity, Dr. Agresta was vice president and head of clinical development at Agios Pharmaceuticals, Inc. During Dr. Agresta’s six plus years at Agios, he was responsible for the successful development of novel targeted oncology medicines, including IDHiFA® for patients with IDH2 mutation positive AML and TIBSOVO® for patients with IDH1 mutation positive AML, as well as the development of the targeted agent, AG-348, currently in Phase 3 development for patients with pyruvate kinase deficiency, a rare genetic disease. Prior to Agios, Dr. Agresta held positions of responsibility in oncology clinical development, Phases I-III, at Merrimack Pharmaceutical and Genentech, Inc., including the development of Onivyde®, for patients with pancreatic cancer and Kadcyla®, a novel targeted oncology medicine for patients with HER2 positive breast cancer. Prior to his industry experience, Dr. Agresta was on the oncology faculty at the Moffitt Cancer Center where he specialized in adolescent sarcoma care and participated in numerous industry trials.